Want to see NL:CRBN full AI Analyst Report?
Top Page
Corbion NV
(CRBN)
Select Model
Select Model
Rating:59Neutral
Price Target:
€21.00
▲(11.82% Upside)
Action:Downgraded
Date:03/02/26
The score is primarily supported by improving financial quality (deleveraging and a sustained rebound to positive free cash flow) and a reasonable valuation with a solid dividend yield. It is held back by weak technicals (price below key short-term averages and oversold momentum) and fundamental headwinds from multi-year revenue softness and uneven net income.
Positive Factors
Leverage Reduction
Material deleveraging over 2023–2025 meaningfully lowers balance-sheet risk and interest burden. This enhances financial flexibility for strategic investment, dividend support or further debt paydown and improves resilience across economic cycles, supporting durable capital allocation.
Negative Factors
Multi-year Revenue Softness
A multi-year decline in revenue constrains scale economies and market positioning. Persistent top-line weakness makes growth reliant on new products, market share gains or structural demand shifts for bio-based ingredients, raising execution risk over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Leverage Reduction
Material deleveraging over 2023–2025 meaningfully lowers balance-sheet risk and interest burden. This enhances financial flexibility for strategic investment, dividend support or further debt paydown and improves resilience across economic cycles, supporting durable capital allocation.
Read all positive factors
Corbion NV (CRBN) vs. iShares MSCI Netherlands ETF (EWN)
Market Cap
€1.16B
Dividend Yield3.5%
Average Volume (3M)126.91K
Price to Earnings (P/E)15.6
Beta (1Y)0.88
Revenue Growth-1.61%
EPS Growth38.58%
CountryNL
Employees2,408
SectorGeneral
Sector StrengthN/A
IndustryFood Confectioners
Share Statistics
EPS (TTM)1.29
Shares Outstanding58,250,310
10 Day Avg. Volume117,838
30 Day Avg. Volume126,914
Financial Highlights & Ratios
PEG Ratio-0.24
Price to Book (P/B)1.45
Price to Sales (P/S)0.85
P/FCF Ratio11.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€23.83Price Target Upside26.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)1.37
Revenue Forecast (FY)€1.27B
Corbion NV Business Overview & Revenue Model
Company Description
Corbion NV engages in the development, production, sale, and distribution of ingredients for food and biochemicals. It operates through the following segments: Food and Biochemicals. The Food segment provides biobased ingredients for the food indu...
How the Company Makes Money
Corbion makes money primarily by manufacturing and selling specialty ingredients and biobased chemicals to business customers. A key revenue stream comes from food-related products—such as preservation and antimicrobial solutions and other functio...
Corbion NV Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
63
Positive
Cash Flow
66
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.27B | 1.29B | 1.44B | 1.46B | 1.07B |
| Gross Profit | 330.30M | 312.10M | 305.40M | 324.30M | 265.80M |
| EBITDA | 202.30M | 172.00M | 198.00M | 194.00M | 140.10M |
| Net Income | 74.80M | 192.20M | 72.90M | 90.00M | 78.30M |
Balance Sheet | |||||
| Total Assets | 1.42B | 1.55B | 1.70B | 1.72B | 1.36B |
| Cash, Cash Equivalents and Short-Term Investments | 44.70M | 49.30M | 70.20M | 58.20M | 42.20M |
| Total Debt | 481.10M | 509.20M | 785.50M | 759.20M | 503.20M |
| Total Liabilities | 674.30M | 773.80M | 1.06B | 1.10B | 806.50M |
| Stockholders Equity | 742.60M | 772.50M | 636.20M | 625.70M | 554.10M |
Cash Flow | |||||
| Free Cash Flow | 92.70M | 99.90M | 16.10M | -182.60M | -122.00M |
| Operating Cash Flow | 160.90M | 184.10M | 165.40M | 53.20M | 26.70M |
| Investing Cash Flow | -70.10M | 166.00M | -146.80M | -213.30M | -123.70M |
| Financing Cash Flow | -93.80M | -371.70M | -5.30M | 173.90M | 85.90M |
Corbion NV Technical Analysis
Positive
18.78
Price Trends
19.13
Positive
18.84
Positive
18.01
Positive
Market Momentum
0.32
Positive
54.89
Neutral
24.90
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NL:CRBN, the sentiment is Positive. The current price of 18.78 is below the 20-day moving average (MA) of 19.97, below the 50-day MA of 19.13, and above the 200-day MA of 18.01, indicating a bullish trend. The MACD of 0.32 indicates Positive momentum. The RSI at 54.89 is Neutral, neither overbought nor oversold. The STOCH value of 24.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NL:CRBN.
Corbion NV Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | €548.03M | 11.20 | 14.57% | 4.66% | 14.84% | 59.15% | |
64 Neutral | €4.73B | 21.43 | 10.83% | 2.83% | 1.08% | -24.24% | |
62 Neutral | €10.32B | 16.24 | 14.61% | 3.38% | -7.05% | 32.41% | |
59 Neutral | €1.16B | 15.58 | 8.84% | 3.50% | -1.61% | 38.58% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
50 Neutral | €847.40M | -3.07 | ― | 229.25% | ― | ― | |
46 Neutral | €192.33M | -4.36 | -26.08% | ― | -30.63% | 43.45% |
* General Sector Average
NL:CRBN
Corbion NV
20.10
2.80
16.21%
NL:AKZA
Akzo Nobel NV
59.10
1.87
3.26%
NL:AVTX
Avantium N.V.
7.42
-1.16
-13.54%
NL:FFARM
ForFarmers N.V.
6.27
2.46
64.74%
NL:IMCD
IMCD N.V.
79.08
-32.96
-29.42%
NL:OCI
OCI N.V.
4.03
-0.82
-16.87%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.